|
Aug 4
|
AB Science announces the successful completion of a 2.55 million euros private placement
|
|
Jul 30
|
AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML
|
|
Jul 24
|
AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS
|
|
Jun 23
|
AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease
|
|
May 15
|
AB Science today reports a new publication in the scientific journal PLOS One, showing promising neuroprotective effects of masitinib
|
|
May 12
|
AB Science reports its revenues for the year 2024 and provides an update on its activities
|
|
Oct 10
|
AB Science: Revenues for the first half of 2024 and update on AB Science’s activities
|
|
Jan 15
|
AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis
|
|
Nov 28
|
AB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease
|
|
Nov 27
|
AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”
|
|
Sep 29
|
AB Science today reports its revenues for the first half of 2023 and provides an update on its activities
|